MedTrace Logo

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

NCT04916236 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-01-24

No results posted yet for this study

Summary

This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.

Conditions

Interventions

DRUG

RMC-4630

* SHP2-inhibitor * Powder in capsule * Administered on day 1 and day 2 of every week

DRUG

LY3214996

* ERK inhibitor * Powder in capsule * Administered every day

Sponsors & Collaborators

  • Lustgarten Foundation

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Emile Voest, MD, PhD · Netherlands Cancer Institute - Antoni van Leeuwenhoek

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916236 on ClinicalTrials.gov